This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-07. Anything still debated is marked as such rather than presented as settled.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
== Origin == GHRH is released from neurosecretory nerve terminals of these arcuate neurons, and is carried by the hypothalamo-hypophyseal portal system to the anterior pituitary gland, where it stimulates growth hormone (GH) secretion by stimulating the growth hormone-releasing hormone receptor. GHRH is released in a pulsatile manner, stimulating similar pulsatile release of GH. In addition, GHRH promotes slow-wave sleep directly. Growth hormone is required for normal postnatal growth, bone growth, regulatory effects on protein, carbohydrate, and lipid metabolism.
=== Cephadroxil === Cefadroxil is an antibiotic. Bristol-Myers Squibb (BMS) patented the "Bouzard form" under US Patent No. 4,504,657 ('657) in 1985. The patenting took 6 years due to disputes about polymorphs. An earlier patent (US Patent No. 3,781,282) covered a different form, the "Micetich form". Attempts to replicate the Micetich form according to Example 19 in the '282 patent consistently yielded the Bouzard form, leading to challenges that the '657 patent was already inherent in the '282 patent, thus invalidated by prior art. BMS argued that the prevalence of the Bouzard form in manufacturing facilities led to unintentional seeding. Experimental tests of the seeding theory were ambiguous, but eventually the patent was granted. Later, Zenith Laboratories marketed a cefadroxil hemihydrate. BMS sued for "gastrointestinal infringement", claiming it converted to the patented Bouzard form in the stomach. The case hinged on the interpretation of X-ray diffraction data, with BMS arguing it demonstrated the presence of the Bouzard form in patients who ingested Zenith's product. However, the court sided with Zenith.
Co2+ + 3/2 S2O2−4 + 6 OH− + 4 CO → Co(CO)−4 + 3 SO2−3 + 3 H2O Some metal carbonyls are prepared using CO directly as the reducing agent. In this way, Hieber and Fuchs first prepared dirhenium decacarbonyl from the oxide:
the type of item being carried. For example, a kettle could fit into the category 'household goods'. how large the shipment is, in terms of both item size and quantity. how long the item for delivery will be in transit. Shipments are typically categorized as household goods, express, parcel, and freight shipments:
=== Food waste reduction === Approximately one-third of all food produced globally is wasted. Innovative food tech solutions are being developed to address this issue. For example, Apeel Sciences has developed an edible coating that extends the shelf life of fruits and vegetables, reducing spoilage and waste.
Sources: en.wikipedia.org
President Paul Kruger called a closed council, including Jan Gerrit Bantjes, to discuss the growing problem and it was decided to put a heavy tax on the sale of dynamite to non-Boer residents. Jan G. Bantjes, fluent in both spoken and written Dutch and English, was a close confidant of Paul Kruger with their link dating to the Great Trek days. Jan's father, Jan Gerritze Bantjes, had given Paul Kruger his elementary education during the trek and Jan Gerritse was part of his inner core of associates. This closed council would be the committee which set the Transvaal Republic on a collision course with Great Britain and the Anglo-Boer War 1899-1902 and which set German feelings toward Britain at boiling point by siding with the Boers. Because of this applied dynamite tax, considerable discontent and tensions began to rise. As Johannesburg was largely an Uitlander city, non-boer leaders there began to discuss the proposals for an insurrection. Cecil Rhodes, Prime Minister of the Cape Colony, had a desire to incorporate the Transvaal and the Orange Free State in a federation under British control. Having combined his commercial mining interests with Alfred Beit to form the De Beers Mining Corporation, the two men also wanted to control the Johannesburg gold mining industry. They played a major role in fomenting Uitlander grievances. Rhodes later told the journalist W.T. Stead that he feared that a Uitlander rebellion would cause trouble for Britain if not controlled by him:
polyploid (of a cell or organism) Having more than two homologous copies of each chromosome; i.e. any ploidy level that is greater than diploid. Polyploidy may occur as a normal condition of chromosomes in certain cells or even entire organisms, or it may result from errors in cell division or mutations causing the duplication of the entire chromosome set.
Tolkien wrote a brief "Sketch of the Mythology", which included the tales of Beren and Lúthien and of Túrin; and that sketch eventually evolved into the Quenta Silmarillion, an epic history that Tolkien started three times but never published. Tolkien desperately hoped to publish it along with The Lord of the Rings, but publishers (both Allen & Unwin and Collins) declined. Moreover, printing costs were very high in 1950s Britain, requiring The Lord of the Rings to be published in three volumes. The story of this continuous redrafting is told in the posthumous series The History of Middle-earth, edited by Tolkien's son, Christopher Tolkien. From around 1936, Tolkien began to extend this framework to include the tale of The Fall of Númenor, which was inspired by the legend of Atlantis. Tolkien appointed his son Christopher to be his literary executor, and he (with assistance from Guy Gavriel Kay, later a well-known fantasy author in his own right) organized some of this material into a single coherent volume, published as The Silmarillion in 1977. It received the Locus Award for Best Fantasy novel in 1978.
== Prognosis == Proper treatment of SAAM often results in full recovery. Recovery can occur even with persistently elevated creatine kinase (CK) levels. Conversely, some people with SAAM do not regain full muscle strength despite the normalization of their CK levels. Longitudinal analysis of a patient cohort revealed that the majority of patients (85%) over 60 years old recovered full strength within four years, compared to less than half of patients below 52 years old, indicating that age during disease onset may be an important prognostic determinant. Once strength recovers, immunosuppressive medications should be tapered. Relapse remains possible during tapering efforts, and some people require long-term immunosuppression. An affected person is more likely to experience permanent muscle damage if they do not receive adequate treatment for a long time. Muscle weakness occurs due to the replacement of some muscle with fatty tissue.
Soon after, Colombia achieved some degree of political stability, which was interrupted by a bloody conflict that took place between the late 1940s and the early 1950s, a period known as La Violencia ("The Violence"). Its cause was mainly mounting tensions between the two leading political parties, which subsequently ignited after the assassination of the Liberal presidential candidate Jorge Eliécer Gaitán on 9 April 1948. The ensuing riots in Bogotá, known as El Bogotazo, spread throughout the country and claimed the lives of at least 180,000 Colombians. Colombia entered the Korean War when Laureano Gómez was elected president. It was the only Latin American country to join the war in a direct military role as an ally of the United States. Particularly important was the resistance of the Colombian troops at Old Baldy. The violence between the two political parties decreased first when Gustavo Rojas deposed the President of Colombia in a coup d'état and negotiated with the guerrillas, and then under the military junta of General Gabriel París.
Sources: en.wikipedia.org
Verbena officinalis in the CalPhotos photo database, University of California, Berkeley "Verbena officinalis". Calflora. Berkeley, California: The Calflora Database. "Verbena officinalis". Plants for a Future.
== VD-Hpα == In contrast to RVD-Hpα which produces antagonist or inverse agonist activity at CB1 under most conditions but acts as an agonist at CB2, the shorter 11-amino acid peptide fragment VD-Hpα produces agonist effects at CB1 but has little or no activity at CB2, producing centrally mediated analgesic effects, hypothermia and increased sleep in animal studies through activation of the CB1 receptor. Hybrid peptides combining VD-Hpα with peptide agonists for neuropeptide VF and opioid receptors have also been developed to produce dual acting compounds.
AATCC—the American Association of Textile Chemists and Colorists— is a 501(c)(6) not-for-profit professional association that provides test method development, quality control materials, educational development, and networking for textile and apparel professionals throughout the world. The American Association of Textile Chemists and Colorists (AATCC) develop the test methods the textile industry use to ensure product quality. AATCC is the world's leading not-for-profit association serving textile professionals since 1921. AATCC, headquartered in Research Triangle Park, Durham, N.C., USA, provides test method development, quality control materials, and professional networking for thousands of members throughout the world.
=== Production of other elements === Americium-241 is sometimes used as a starting material for the production of other transuranic elements and transactinides – for example, neutron bombardment of 241Am yields 242Am:
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.